Strain Information | |
---|---|
Image | |
BRC No. | RBRC00915 |
Type | Targeted Mutation Congenic |
Species | Mus musculus |
Strain name | C.Cg-Irf9<tm1Ttg>/TtgRbrc |
Former Common name | IRF-9 KO/BALB/c; BALB/cAJcl-Isgf3g<tm1>, IRF-9 Knockout mouse, BALB/c |
H-2 Haplotype | |
ES Cell line | TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1] |
Background strain | BALB/cAJcl |
Appearance | albino |
Strain development | Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations). |
Strain description | IRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916). |
Colony maintenance | Homozygote x Homozygote |
References | Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, Kashiwazaki Y, Tarutani M, Tan R S, Takasugi T, Matsuyama T, Mak T W, Noguchi S, Taniguchi T Genes Cells, 1, 115-124 (1996). 9078371 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Irf9 | interferon regulatory factor 9 | 14 | Irf9 | targeted mutation 1, Tadatsugu Taniguchi | |||
neo | neomycin resistance gene (E. coli) | 14 | mouse phosphoglycerate kinase promoter (PGK promoter) |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | mouse IRF-9 genomic DNA, E. coli neo, mouse phosphoglycerate kinase promoter (PGK promoter) |
Research application | Immunology and Inflammation Research |
Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE. |
Depositor | Tadatsugu Taniguchi (The University of Tokyo) |
Strain Status | Frozen embryos |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- Mouse of the Month May 2005 |
BRC mice in Publications |
---|
Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, Landrigan A, Higgins JP, Tibshirani R, Utz PJ. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 118(4) 1417-26(2008) 18340381 |
Martinet V, Tonon S, Torres D, Azouz A, Nguyen M, Kohler A, Flamand V, Mao CA, Klein WH, Leo O, Goriely S. Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8(+) T cells. Nat Commun 6 7089(2015) 25953241 |